Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

Yoshiki Terada*1, Hirohisa Nakamae1, Ran Aimoto1, Hiroshi Kanashima2, Erina Sakamoto2, Mizuki Aimoto1, Eri Inoue1, Hideo Koh1, Takahiko Nakane1, Yasunobu Takeoka1, Masahiko Ohsawa3, Ki-Ryang Koh1, Takahisa Yamane1, Yoshitaka Naka04, Kensuke Ohta5, Atsuko Mugitani6, Hirofumi Teshima2 and Masayuki Hino1

Address: 1Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan, 2Department of Hematology, Osaka City General Hospital, Osaka, Japan, 3Department of Pathology, Graduate School of Medicine, Osaka City University, Osaka, Japan, 4Department of Hematology, Wakakoukai Hospital, Osaka, Japan, 5Department of Hematology, Saiseikai Nakatsu Hospital, Osaka, Japan and 6Department of Hematology, Seichokai Fuchu Hospital, Osaka, Japan

Email: Yoshiki Terada* - teraday@med.osaka-cu.ac.jp; Hirohisa Nakamae - hirohisa@msic.med.osaka-cu.ac.jp; Ran Aimoto - ran-hmr2@med.osaka-cu.ac.jp; Hiroshi Kanashima - YQQ01127@nifty.ne.jp; Erina Sakamoto - chorina@med.osaka-cu.ac.jp; Mizuki Aimoto - aimoto@med.osaka-cu.ac.jp; Eri Inoue - eri-w@med.osaka-cu.ac.jp; Hideo Koh - hide_koh@med.osaka-cu.ac.jp; Takahiko Nakane - taka5450002@yahoo.co.jp; Yasunobu Takeoka - takeoka@msic.med.osaka-cu.ac.jp; Masahiko Ohsawa - mohsawa@med.osaka-cu.ac.jp; Ki-Ryang Koh - kkoh@med.osaka-cu.ac.jp; Takahisa Yamane - Yamane@med.osaka-cu.ac.jp; Yoshitaka Nakao - m8541228@msic.med.osaka-cu.ac.jp; Kensuke Ohta - kenohta@med.osaka-cu.ac.jp; Atsuko Mugitani - _a_mugitani@seichokai.or.jp; Hirofumi Teshima - hteshima@ocgh.hospital.city.osaka.jp; Masayuki Hino - hinom@med.osaka-cu.ac.jp

* Corresponding author

Abstract

Background: Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly improved outcome in diffuse large B-cell lymphoma (DLBL). However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma.

Methods: We retrospectively evaluated the impact of the RDI of initial chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) on outcome in 100 newly diagnosed DLBL patients.

Results: A multivariate Cox regression model showed that RDI trended towards a significant association with mortality (hazard ratio per 0.1 of RDI = 0.8; 95% confidence interval 0.6–1.0; P = 0.08). Additionally, on multivariate logistic analysis, advanced age was a significant factor for reduced RDI.
Conclusion: Our data suggest that in DLBL patients, mortality was affected by RDI of R-CHOP as the initial treatment, and the retention of a high RDI could therefore be crucial.

Background
Aggressive lymphoma is known to be a highly chemosensitive disease. Therefore, over the past few decades, constant attempts have been made to develop various types of combination chemotherapy including first generation combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) [1]. However, particularly in patients with aggressive lymphoma in the higher International Prognostic Index (IPI) risk group, satisfactory outcomes have not been achieved, with a five-year survival of less than 50% [2].

Several retrospective studies demonstrated that the relative dose intensity (RDI) of combination chemotherapy significantly influences survival in aggressive lymphoma [3-7]. Moreover, rituximab, a chimeric monoclonal anti-CD20 antibody combined with CHOP chemotherapy (R-CHOP) has improved outcome in patients with diffuse large B-cell lymphoma (DLBL) [8,9]. Rituximab has direct, complement-dependent and antibody-dependent cellular cytotoxicity against B-cells. The drug also sensitizes B-lymphoma cells to chemotherapy [10]. Therefore, a combined approach with rituximab plus CHOP could conceivably modify the effects of RDI. However, there is no evidence that even in combination chemotherapy with rituximab that higher RDI improves the outcome for aggressive B-cell type lymphoma. Hence, in our study, we retrospectively analyzed the impact of the RDI of chemotherapy with R-CHOP as an initial treatment on the survival of patients with DLBL, and furthermore, we determined the factors influencing RDI.

Methods
Eligibility
Patients were eligible if they had newly diagnosed DLBL according to the World Health Organization classification or the Revised European-American Lymphoma classification [11,12]. As initial chemotherapy, they received R-CHOP with more than three consecutive courses between December 2003 and February 2008 at five institutions, Osaka City University Hospital, Osaka City General Hospital, Seichokai Fuchu Hospital, Saiseikai Nakatu Hospital and Wakakoukai Hospital. One hundred patients who had complete records of drug dose, time intervals, and prophylactic G-CSF use were deemed eligible for this study. Patients were excluded if they had T-cell lymphoma or prior radiotherapy before CHOP. Clinical data and follow-up information were obtained by reviewing the patients' medical records. All patients provided written informed consent for their treatment.

Patient Characteristics
We analyzed 100 newly diagnosed DLBL patients treated with initial R-CHOP chemotherapy. The clinical characteristics of all the patients are shown in Table 1. Median age of the patients was 60 years. Of the 100 patients, 45 were 61 years or older. Sixty-two patients had advanced-stage (stage III, IV) disease, and 23 patients had poor performance status (PS). In 52 patients, lactate dehydrogenase level (LDH) was high (over the upper limit of normal). Thirty-two patients had two or more extranodal disease sites. Forty-two patients were in the higher IPI risk group (high or high-intermediate risk group). In 26 patients, serum albumin levels were < 3.5 g/dl. The median number of CHOP courses was 6 (range, 3–8). The median number of R-CHOP cycles for patients with localized disease was 6 (range, 3–8), and there was no significant difference in the number of cycles between patients with localized disease and those with advanced disease.

Table 1: Patient characteristics

| Characteristic                           | n. (%) |
|-----------------------------------------|--------|
| Total number of patients                | 100    |
| Age                                     |        |
| < 61                                    | 55 (55)|
| ≥ 61                                    | 45 (45)|
| Clinical Stage                          |        |
| I, II                                   | 38 (38)|
| III, IV                                 | 62 (62)|
| Performance status                      |        |
| 0–1                                     | 23 (23)|
| 2–4                                     |        |
| LDH                                     |        |
| N                                       | 52 (52)|
| < N                                     | 48 (48)|
| Extranodal lesion                       |        |
| 0–1                                     | 68 (68)|
| 2–4                                     | 32 (32)|
| IPI                                     |        |
| Low/low-intermediate                    | 58 (58)|
| High/high-intermediate                  | 42 (42)|
| Albumin                                 |        |
| < 3.5 g/dl                              | 26 (26)|
| ≥ 3.5 g/dl                              | 74 (74)|
| Prophylactic G-CSF                      |        |
| yes                                     | 62 (62)|
| no                                      | 38 (38)|

N: normal range; IPI: international prognostic index; G-CSF: granulocyte colony-stimulating factor
Chemotherapy Regimen

The CHOP chemotherapy consisted of cyclophosphamide (750 mg/m² given intravenously on Day 1), doxorubicin (50 mg/m² given intravenously on Day 1), vincristine (1.4 mg/m² (maximum 2 mg/body), given intravenously on Day 1) and prednisolone (100 mg/day, given orally on Day 1 to 5) [13]. The treatment course was repeated every three weeks, unless peripheral leukocyte or platelet counts became too low to administer the next cycle. A time limit for peripheral blood count recovery before administration of the next cycle of chemotherapy was not adopted. In patients who experienced severe neutropenia, thrombocytopenia and/or infections, or febrile neutropenia during cycles, the doses of cyclophosphamide, doxorubicin and vincristine in the subsequent cycle were reduced at the discretion of clinical physicians. Moreover, the dose of vincristine was also reduced depending on the occurrence and degree of neurologic toxicity. Rituximab was administered at a dose of 375 mg/m² per cycle for up to 8 cycles concurrently with CHOP, as long as the disease responded to the treatment. Seven patients received involved-field radiation therapy of 30–40 Gy.

G-CSF was given if patients experienced neutropenia with an absolute neutrophil count of less than 500/μl during cycles. Prophylactic G-CSF was administered at the physician’s discretion to prevent the development of neutropenia in 62 patients who had experienced infections associated with neutropenia in the prior cycle [14]. In these patients, the median number of CHOP cycles with prophylactic G-CSF was 3 (range, 1–6).

Calculation of Dose Intensity (DI)

The DI of each agent was calculated by dividing the total received dose of the agent by the number of weeks of treatment [3]. The relative total dose intensity (RTDI) of each agent was calculated by expressing the total delivered dose of agent per unit time (week) as a percentage of the target dose. The averaged RDI (ARDI) was calculated by expressing the average delivered dose of the chemotherapy regimen per unit time (week) as a percentage of the target dose. In this study, the ARDI was calculated by averaging the RTDIs of cyclophosphamide and doxorubicin in all the chemotherapy courses, and hereinafter the ARDI of R-CHOP is simply referred to as the "RDI."

Statistical Methods

Overall survival (OS) was calculated from the initiation of R-CHOP chemotherapy to the time of death or to the time of the last follow-up. Progression free survival (PFS) was calculated from the initiation of R-CHOP chemotherapy to the time of relapse, progression, death or the last follow-up. Both OS and PFS were calculated using the Kaplan-Meier method. Survival curves of the different groups were compared using the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were used to assess the effects of the pretreatment prognostic factors on overall survival [15]. Multiple logistic analysis was applied to identify factors influencing RDI. P values less than 0.05 were considered to be statistically significant, and all tests were two-tailed. All analyses were performed using SPSS version 15.0 J (SPSS, Chicago, IL).

Results

RDI

In all patients, the calculated medians of the RTDI of doxorubicin and cyclophosphamide were 88.8% and 88.6%, respectively and the median RDI for all cycles of R-CHOP given was 87.9%.

Survival Analysis

We registered 14 deaths. With a median follow-up of 21.2 months, the three-year OS in all cases, in the group with a higher RDI (above the median) and in the group with a lower RDI (below the median) was 81.6%, 92.1% and 74.2%, respectively (Figure 1). The three-year PFS in all cases, in the group with a higher RDI (above the median) and in the group with a lower RDI (below the median) was 56.3%, 58.7% and 54.0%, respectively.

In the univariate analysis to identify prognostic factors for OS, RDI and IPI were significant factors influencing OS. In a multivariate analysis, RDI tended to be a significant risk factor for mortality [hazard ratio (HR) per 0.1 of RDI = 0.8; 95% confidence interval (CI) 0.6–1.0; P = 0.08] (Table 2).

Factors Influencing RDI

The univariate analyses identified advanced age and higher IPI score as risk factors for reduced RDI. In the multivariate logistic analysis of all these factors, only older age
remained as a factor that retained persistent statistical significance [odds ratio (OR) = 0.4; 95% CI 0.2–0.8; \( P = 0.02 \)]. (Table 3).

**Discussion**

In DLBL patients, our data demonstrated that a high RDI of CHOP trended towards a significant association with better survival, even when the CHOP was combined with rituximab. Only advanced age was identified as a risk factor for reduced RDI.

There are several previous studies of the relationship between the RDI of chemotherapy and survival in aggressive lymphoma. A high RDI of doxorubicin in CHOP, M-BACOD, or MACOP-B chemotherapy [4], a high RDI of each drug (cyclophosphamide, doxorubicin or vincristine) and a high averaged RDI of these three drugs in CHOP for diffuse large cell lymphoma (DLCL) reportedly had a significant, positive impact on survival [5]. In addition, in ACVB chemotherapy for aggressive lymphoma, the averaged RDI of doxorubicin and cyclophosphamide was strongly associated with survival [6]. Furthermore, it was reported that in elderly patients with DLCL who received a higher dose of doxorubicin, the outcomes were comparable to those of young patients [16]. In a recent study, a Belgian group also reported that maintaining a high RDI resulted in a favorable outcome in CHOP chemotherapy for DLBL patients [7].

The addition of rituximab to CHOP or other chemotherapy regimens has reportedly led to a significant improvement in the prognosis of DLBL patients. Interestingly, it was suggested from preclinical models that rituximab chemosensitized drug-resistant B-lymphoma cells through down-regulation of anti-apoptotic factors and endogenous IL-10 expression [17,18], suggesting that rituximab is likely to have a significant therapeutic effect by augmenting the effect of anticancer agents in CHOP in a synergistic fashion and thereby compensating for a low CHOP RDI. However, from our results, it was clear that

**Table 2: Prognostic factors for overall survival**

| Factor                        | Univariate model | Multivariate model |
|-------------------------------|------------------|--------------------|
|                               | HR (95% CI)      | P value            | HR (95% CI)      | P value |
| Age (61 ≤)                    | 2.2 (0.8–6.7)    | 0.15               | -                | -       |
| Sex (male)                    | 2.6 (0.7–9.3)    | 0.14               | -                | -       |
| Stage III, IV                 | 7.6 (1.0–5.8)    | 0.15               | -                | -       |
| Extramedal site (2 ≤)         | 1.7 (0.6–4.8)    | 0.35               | -                | -       |
| LDH (> upper normal limit)    | 1.8 (0.5–5.8)    | 0.34               | -                | -       |
| Performance status (2–4)      | 2.8 (1.0–8.1)    | 0.05               | -                | -       |
| RDI (CPA+DOX) per 0.1         | 0.7 (0.6–0.9)    | 0.02*              | 0.8 (0.6–1.0)    | 0.08    |
| IPI (high/high intermediate)  | 4.7 (1.3–17)     | 0.02*              | 3.8 (1.0–14)     | 0.05    |
| Albumin (3.5 mg/dl ≤)         | 0.7 (0.4–1.2)    | 0.20               | -                | -       |
| Prophylactic G-CSF            | 1.6 (0.5–4.9)    | 0.44               | -                | -       |

HR: hazard ratio; CI: confidence interval; CPA: cyclophosphamide; DOX: doxorubicin; G-CSF: granulocyte colony-stimulating factor

**Table 3: Factors influencing RDI (above the Median): Univariate and Multivariate analysis**

| Factor                        | Univariate model | Multivariate model 1 | Multivariate model 2 |
|-------------------------------|------------------|----------------------|----------------------|
|                               | OR (95% CI)      | P value              | OR (95% CI)          | P value              | OR (95% CI) | P value |
| Age (61 ≤)                    | 0.3 (0.2–0.8)    | 0.0099*              | 0.4 (0.2–0.8)        | 0.06                 | 0.4 (0.2–0.8) | 0.02* |
| Sex (male)                    | 1.3 (0.6–2.9)    | 0.54                 | -                    | -                    | -            | -       |
| Stage III, IV                 | 0.8 (0.4–1.9)    | 0.68                 | -                    | -                    | -            | -       |
| Extramedal site (2 ≤)         | 1.0 (0.4–2.3)    | 1.00                 | -                    | -                    | -            | -       |
| LDH (> upper normal limit)    | 0.5 (0.2–1.2)    | 0.11                 | -                    | -                    | 0.6 (0.3–1.4) | 0.24 |
| Performance status (2–4)      | 0.6 (0.2–1.5)    | 0.24                 | -                    | -                    | -            | -       |
| IPI (high/high intermediate)  | 0.4 (0.2–1.0)    | 0.04*                | 0.6 (0.3–1.6)        | 0.33                 | -            | -       |
| Alb (0.5 mg/dl ≤)             | 0.8 (0.5–1.4)    | 0.50                 | -                    | -                    | -            | -       |
| Prophylactic G-CSF +          | 1.7 (0.7–3.8)    | 0.22                 | -                    | -                    | -            | -       |

IPI: international prognostic index. G-CSF: granulocyte colony-stimulating factor
maintaining a high RDI remained crucial in the use of R-CHOP for DLBL patients, in a similar fashion to CHOP alone.

We identified advanced age as the only factor that reduced RDI. A nationwide study of RDI in CHOP-like chemotherapies in patients with non-Hodgkin’s lymphoma (NHL) in the United States also showed that older age was a risk factor for reduced RDI, in addition to lack of use of prophylactic colony stimulating factor (CSF), advanced disease stage, poor PS and a lower serum albumin level [19]. Moreover, the study indicated that prophylactic CSF use is important in maintaining a high RDI, particularly in elderly patients. The American Society of Clinical Oncology update guideline for the use of CSF, also recommends use of prophylactic CSF during curative and intensive chemotherapy for elderly patients with DLCL, to reduce the incidence of febrile neutropenia and infections [14]. In addition, according to the European Organization for Research and Treatment of Cancer guideline on the use of G-CSF, when dose-dense or dose-intense chemotherapy has a survival benefit, prophylactic G-CSF use is recommended, especially in elderly patients [20]. Indeed, in a prospective study on prediction of febrile neutropenia in the first cycle of chemotherapy for NHL, elderly patients were identified as candidates for primary CSF prophylaxis [21]. Taking into account these reports as well as our results, prophylactic use of CSF could be recommend, at least in elderly patients with DLBL who are scheduled to receive R-CHOP chemotherapy in order to maintain RDI.

As our study was a retrospective cohort study with a small study population and/or short median follow-up periods, it was inevitable that treatment bias due to physician discretion in making treatment decisions would arise. Therefore, prospective randomized trials will be required to confirm the value of maintaining a high RDI. For instance, an alternative strategy to intensify RDI by shortening the intervals between cycles of chemotherapy, such as bi-weekly CHOP, may be promising [22]. Indeed, Groupe d’Etudes de Lymphomes de L’Adulte (GELA) is now conducting a phase III prospective randomized trial to assess the difference between eight cycles of bi-weekly R-CHOP and three-weekly R-CHOP. The results of this prospective randomized trial are awaited.

**Conclusion**

In DLBL patients, mortality was affected by the RDI of R-CHOP as the initial treatment and the retention of high RDI could be crucial, especially in elderly patients. To optimize the RDI of conventional chemotherapy in order to achieve better outcomes for patients with DLBL, further investigation of RDI will be required.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

All the authors contributed as mentioned. YT and HN conceived of the study and drafted the manuscript. RA obtained clinical data and follow-up information by reviewing the patients’ medical records. MO reviewed the pathological specimens in this study. HK, ES, MA, EI, HK, TN, YT, MO, KK, TY, YN, KO, AM, and HT participated in designing the study and helped to write the paper. MH supervised the entire study. All authors have read and approved the final manuscript.

**Acknowledgements**

We thanks for clinical research nurse. Yukari Umemoto (Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan) for assistance in obtaining clinical data and follow-up information.

**References**

1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Colton CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993, 328:1002-6.

2. International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987-94.

3. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y: Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. J Clin Oncol 1990, 8:563-77.

4. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic significance of actual dose intensity in diffuse large cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990, 8:563-77.

5. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y: Survival of diffuse large cell lymphoma. Ann Oncol 1993, 4:651-6.

6. Bosy A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008, 87:277-83.

7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bosy A, Morel P, Herbrecht R, Reyes F, Coiffier B: Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: Application to LNH-87 protocol. The GELA (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 1993, 4:651-6.

8. Pfreundschuh M, Trumper L, Osterborg A, Pettenegil R, Trnney M, Imrie K, Ma D, Gill D, Walewska J, Zinzani PL, Stahel R, Kvaloy S, Shlipilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendla M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group: CHOP-like chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346:235-42.

9. Demidem A, Lam T, Alas S, Harirhan K, Hanna N, Banavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensi-
tizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Bother Radiopharm 1997, 12:177-186.
11. Jaffe ES, Harris NL, Vardiman J, Stein H. Pathology and genetics: neoplasms of the hematopoietic and lymphoid tissues. In World Health Organization Classification of Tumours Edited by: Kleihues P, Sobin LH. Lyon: IARC Press; 2001:237-53.
12. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-92.
13. McKeelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Groesse PN, Gutierrez J, Colman C, Moon TE. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484-93.
14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett Charles L, Cantor Scott B, Crawford Jeffrey, Cross Scott D, Demetri George, Desch Christopher E, Pizzo Philip A, Schiffer Charles A, Schwartzberg Lee, Somlo George, Wade James C, Wade James L, Winn Rodger J, Wozniak Antoinette J, Wolfe Antonio C. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 1:3187-205.
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972, 34:187-220.
16. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003, 98:2651-6.
17. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530-40.
18. Als S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137-44.
19. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004, 22:4302-11.
20. De Aaprischul M, Schubert J, Zipert M, Schmitz M, Mohren M, Lengfelder E, Reiser M, Hickenberg C, Clemens M, Peter N, Bokemeyer C, Einemacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poechel V, Schmitz N, Rube C, Feller AC, Loefler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-16.

Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
· available free of charge to the entire biomedical community
· peer reviewed and published immediately upon acceptance
· cited in PubMed and archived on PubMed Central
· yours — you keep the copyright